(Q35182946)

7 August 2017

1 reference

title

Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions (English)

1 reference

7 August 2017

Sharon Goble

1

1 reference

7 August 2017

Harry D Bear

series ordinal

2

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Surgical Clinics of North America

7 August 2017

published in

1 reference

7 August 2017

volume

83

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

943-971

1 reference

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Promotion of microtubule assembly in vitro by taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

1 reference

7 January 2021

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Coping with toxicities of docetaxel (Taxotere)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Taxane/anthracycline combinations: setting a new standard in breast cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Comprehensive management of locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Multimodal treatment of locoregionally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Combination of docetaxel and doxorubicin as first-line chemotherapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900071-9

7 January 2021

10.1016/S0039-6109(03)00071-9

Identifiers

DOI

1 reference

7 August 2017

1 reference